Sun Pharmaceutical Recalls Carbidopa and Levodopa Tablets for Dissolution Failures
Sun Pharmaceutical Industries is recalling 8,537 bottles of Carbidopa and Levodopa tablets because they failed dissolution specifications.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly states the agency classification is Class II. According to the rubric, if the agency's own classification is FDA Class I or USDA Class I, the score is never below 4; however, FDA Class II is generally mapped to Severe (4) in this specific rubric structure where Class I is Critical (5) and Class II is Severe (4) due to the potential for adverse health consequences.
Plain-English summary
Sun Pharmaceutical Industries, Inc. is recalling 8,537 bottles of Carbidopa and Levodopa Tablets USP 25 mg/250 mg. The affected products are distributed in 100-count and 500-count bottles and are available nationwide. The recall was initiated because the tablets failed to meet dissolution specifications.
The specific lot numbers and expiration dates for the recalled 100-count bottles are JKP5530A (Exp. 12/17), JKP3991A (Exp. 11/17), and JKR6535A (Exp. 07/18). The lot number and expiration date for the recalled 500-count bottles are JKP5529A (Exp. 11/17). The products are identified by NDC 62756-519-88 for 100-count bottles and NDC 62756-519-13 for 500-count bottles.
Consumers who have these specific products should stop using them and contact their healthcare provider or pharmacist for guidance on obtaining a replacement. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- CARBIDOPA AND LEVODOPA (CARBIDOPA AND LEVODOPA)
- Brand
- CARBIDOPA AND LEVODOPA
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 8,537
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- a) JKP5530A Exp. 12/17
- JKP3991A Exp. 11/17
- JKR6535A Exp. 07/18 b) JKP5529A Exp. 11/17
UPCs (3)
- 0362756517882
- 0362756519886
- 0362756518889
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Sun Pharmaceutical Industries, Inc.
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17